Cancers, Vol. 16, Pages 1453: Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma
Cancers, Vol. 16, Pages 1453: Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma
Cancers doi: 10.3390/cancers16081453
Authors:
Sami Fares
Chase J. Wehrle
Hanna Hong
Keyue Sun
Chunbao Jiao
Mingyi Zhang
Abby Gross
Erlind Allkushi
Melis Uysal
Suneel Kamath
Wen Wee Ma
Jamak Modaresi Esfeh
Maureen Whitsett Linganna
Mazhar Khalil
Alejandro Pita
Jaekeun Kim
R. Matthew Walsh
Charles Miller
Koji Hashimoto
Andrea Schlegel
David Choon Hyuck Kwon
Federico Aucejo
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the sixth most diagnosed malignancy worldwide. Serum alpha-fetoprotein (AFP) is the traditional, ubiquitous biomarker for HCC. However, there has been an increasing call for the use of multiple biomarkers to optimize care for these patients. AFP, AFP-L3, and prothrombin induced by vitamin K absence II (DCP) have described clinical utility for HCC, but unfortunately, they also have well established and significant limitations. Circulating tumor DNA (ctDNA), genomic glycosylation, and even totally non-invasive salivary metabolomics and/or micro-RNAS demonstrate great promise for early detection and long-term surveillance, but still require large-scale prospective validation to definitively validate their clinical validity. This review aims to provide an update on clinically available and emerging biomarkers for HCC, focusing on their respective clinical strengths and weaknesse...
Source: Cancers - Category: Cancer & Oncology Authors: Sami Fares Chase J. Wehrle Hanna Hong Keyue Sun Chunbao Jiao Mingyi Zhang Abby Gross Erlind Allkushi Melis Uysal Suneel Kamath Wen Wee Ma Jamak Modaresi Esfeh Maureen Whitsett Linganna Mazhar Khalil Alejandro Pita Jaekeun Kim R. Matthew Walsh Charles Mill Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Vitamin K | Vitamins